Document Detail


Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade.
MedLine Citation:
PMID:  20706133     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: Clinical studies indicate that the remission, regression or both of nephrotic-range albuminuria are exerted by angiotensin II receptor blockers (ARBs) in diabetes. The current study was performed to test the hypothesis that these effects of ARBs are associated with regression of glomerular podocyte injury.
METHODS: We examined the effects of an ARB, olmesartan, on glomerular podocyte injury in type 2 diabetic Otsuka-Long-Evans-Tokushima-Fatty rats with overt albuminuria.
RESULTS: At baseline (55-week-old), diabetic Otsuka-Long-Evans-Tokushima-Fatty rats showed severe albuminuria with desmin-positive areas (an index of podocyte injury) in both superficial and juxtamedullary glomeruli, and podocyte injury was much greater in juxtamedullary than in superficial glomeruli. At 75-week-old, Otsuka-Long-Evans-Tokushima-Fatty rats had developed more severe albuminuria and superficial glomerular podocyte injury, whereas juxtamedullary glomerular podocyte injury did not advance further. Olmesartan (10 mg/kg per day) decreased albuminuria and superficial glomerular desmin staining to levels that were lower than those at baseline, whereas advanced juxtamedullary glomerular podocyte injury was not changed.
CONCLUSION: The current study demonstrates for the first time that juxtamedullary glomerular podocyte injury reaches a severe condition at an earlier time than superficial glomerular podocyte injury during the progression of overt albuminuria in type 2 diabetic rats. Our data also support the hypothesis that the antialbuminuric effects of ARBs are associated with regression of superficial glomerular podocyte injury in type 2 diabetes with nephrotic-range albuminuria.
Authors:
Genei Ihara; Hideyasu Kiyomoto; Hiroyuki Kobori; Yukiko Nagai; Naro Ohashi; Hirofumi Hitomi; Daisuke Nakano; Nicolas Pelisch; Taiga Hara; Takefumi Mori; Sadayoshi Ito; Masakazu Kohno; Akira Nishiyama
Related Documents :
15161763 - Association between mannose-binding lectin and vascular complications in type 1 diabetes.
11382563 - The treatment of hypertension in patients with diabetes.
18084883 - Multiple medical problems following agent orange exposure.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  28     ISSN:  1473-5598     ISO Abbreviation:  J. Hypertens.     Publication Date:  2010 Nov 
Date Detail:
Created Date:  2010-10-15     Completed Date:  2011-02-02     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  2289-98     Citation Subset:  IM    
Affiliation:
Cardiorenal and Cerebrovascular Internal Medicine, Kagawa University Medical School, Kagawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Albuminuria / pathology*
Angiotensin II / metabolism*
Animals
Diabetes Mellitus, Experimental / therapy*
Diabetes Mellitus, Type 2 / therapy*
Disease Models, Animal
Kidney / pathology
Kidney Glomerulus / pathology
Male
Podocytes / pathology
Rats
Rats, Long-Evans
Remission Induction
Sclerosis / pathology
Treatment Outcome
Grant Support
ID/Acronym/Agency:
R01 DK072408/DK/NIDDK NIH HHS; R01 DK072408-01A1/DK/NIDDK NIH HHS; R01DK072408/DK/NIDDK NIH HHS
Chemical
Reg. No./Substance:
11128-99-7/Angiotensin II
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Is periodontal inflammation associated with raised blood pressure? Evidence from a National US surve...
Next Document:  Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular ...